Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (**Withdrawn**) An isolated DNA having a nucleotide sequence comprising any of SEQ ID Nos 1 to 27.

2. (**Withdrawn**) The isolated DNA of claim 1, consisting of any of SEQ ID Nos 1 to 27.

3. (**Cancelled**)

4. (**Withdrawn**) The isolated DNA as claimed in claim 1 , wherein the DNA may be fluorescently labeled.

5. (**Currently Amended**) A method for detection of nucleic acid of a pathogenic infectious agent comprising the sequential steps of:
(a) isolating the nucleic acid of the pathogenic infectious agent,
(b) ~~amplifying~~ pre-amplifying the nucleic acid of the pathogenic infectious agent, and
(c) performing Real Time PCR on the nucleic acid of the pathogenic ~~infectious~~ agent that is pre-amplified in step (b).

6. (**Previously Presented**) A method as claimed in claim 5 wherein the amplifying the nucleic acid of the pathogenic infectious agent comprises PCR, NASBA or any other nucleic acid amplification technique.

7. (**Previously Presented**) The method for nucleic acid detection as claimed in claim 5, wherein Real Time PCR uses fluorescently labeled probes.

8. (**Previously Presented**) The method as claimed in claim 5 wherein the nucleic acid to be detected is DNA or cDNA.

9. (**Previously Presented**) The method as claimed in claim 8 wherein the nucleic acid is SARS coronavirus cDNA.

10. (**Previously Presented**) The method as claimed in claim 5 wherein the method comprises the following steps:

i) extracting the nucleic acid from a biological or environmental sample;

ii) amplifying the nucleic acid using PCR, NASBA or any other nucleic acid amplification technique; and

iii) amplifying and detecting the nucleic acid produced in step (ii) using Real Time PCR.

11. (**Previously Presented**) The method of claim 10 wherein there is an additional step after step (i) if the nucleic acid obtained is RNA, wherein the step comprises converting the RNA to cDNA using reverse transcriptase.

12. (**Previously Presented**) The method as claimed in claim 5 wherein primers and/or probes are used in steps (ii) and (iii).

13. (**Previously Presented**) The method as claimed in claim 12 for the detection of SARS coronavirus cDNA.

14. (**Previously Presented**) The method as claimed in claim 13 wherein the primers and probes used correspond to isolated DNA sequences comprising SEQ ID Nos 1 to 27.

15. (**Previously Presented**) The method as claimed in claim 14 wherein the primers used in step (iii) do not overlap with the probe.

16. (**Previously Presented**) The method as claimed in claim 14 wherein the primer sets used in step (ii) corresponds to any of SEQ ID Nos 1, 2, 3, 4 or 5; and 6, 7, 8, 9 or 10.

17. (**Withdrawn**) The method as claimed in claim 14 wherein the primer set used in step (ii) corresponds to any of SEQ ID Nos 26 and 27.

18. (**Withdrawn**) The method as claimed in claim 14 wherein the primer set used in step (iii) corresponds to any of SEQ ID Nos 11, 12, 13, 14, or 15; and 16, 17, 18, 19 or 20.

19. (**Withdrawn**) The method as claimed in claim 16 wherein the probe used in step (iii) corresponds to any of SEQ ID Nos 21, 22, 23, 24 or 25.

20-25. (**Cancelled**)

26. (**Withdrawn**) A SARS diagnostic test kit comprising two or more isolated DNAs having sequences corresponding to SEQ ID Nos 1 to 27.

27. (**Withdrawn**) A SARS diagnostic test kit as claimed in claim 26 comprising primers corresponding to any of SEQ ID Nos 1, 2, 3, 4 or 5 and 6, 7, 8, 9 or 10.

28. (**Withdrawn**) A SARS diagnostic test kit as claimed in claim 26 comprising primers corresponding to any of SEQ ID Nos 26 and 27.

29. (**Withdrawn**) A SARS diagnostic test kit as claimed in claim 26 comprising primers corresponding to any of SEQ ID NOS 11, 12, 13, 14 or 15 and 16, 17, 18, 19 or 20.

30. (**Withdrawn**) A SARS diagnostic test kit as claimed in claim 29 comprising a probe corresponding to any of SEQ ID Nos 21, 22, 23, 24 or 25.

31. (**Withdrawn**) A diagnostic test kit for detecting SARS coronavirus in a biological or environment sample wherein the kit comprises:

(i) an isolating agent for isolating the SARS coronavirus RNA from the sample; and

(ii) a nucleic acid replicating agent for replicating a target molecule, wherein the target molecule includes: a nucleic acid sequence complementary to at least a portion of the RNA sequence of SARS coronavirus ; and

(iii) a nucleic acid detecting the target molecule, wherein the nucleic acid detecting agent includes the detection molecule.

32. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 31, wherein the target molecule is a cDNA molecule.

33. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 31 , wherein the nucleic acid replicating agent includes a first purified and isolated DNA molecule including: a DNA sequence for binding to at least a portion of the RNA sequence of SARS coronavirus such that the first purified and isolated DNA molecule extends in the presence of an enzyme and DNA nucleotides to generate a DNA sequence including a DNA sequence complementary to at least a portion of the cDNA sequence of SARS coronavirus when the first purified and isolated DNA molecule binds to at least a portion of the cDNA sequence of SARS coronavirus.

34. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 31 , wherein the first DNA sequence encodes either one of the DNA sequences of SEQ ID Nos. 1, 2, 3, 4 or 5 in conjunction with either one of the DNA sequences set forth in SEQ ID Nos. 6, 7, 8, 9 or 10.

35. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 31 , wherein the nucleic acid replicating agent includes a second purified and isolated DNA molecule including: a DNA sequence for binding to at least a portion of the DNA sequence of SARS coronavirus produced by a first round of amplification such that the second purified and isolated DNA molecule extends in the presence of an enzyme and DNA nucleotides to generate a DNA sequence including: a DNA sequence complementary to at least a portion of the cDNA sequence of SARS coronavirus produced during a first round of amplification when the second purified

and isolated DNA molecule binds to at least a portion of the cDNA sequence of SARS coronavirus.

36. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 32 , wherein the second DNA sequence encodes either one of the DNA sequences set forth in SEQ ID Nos. 11, 12, 13, 14 or 15, in conjunction with either one of the DNA sequences set forth in SEQ ID Nos. 16, 17, 18, 19 or 20.

37. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in claim 31 , wherein the replicated DNA product is first diluted prior to the further amplification.

38. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 31 , wherein the detection molecule includes: a DNA sequence encoding at least a portion complementary to the RNA sequence of SARS coronavirus for binding to the target molecule; and a signal generator.

39. (**Withdrawn**) A kit as claimed in Claim 38 wherein the DNA sequence of the first DNA molecule does not overlap with the second DNA molecules.

40. (**Withdrawn**) A kit as claimed in Claim 38 wherein the signal generator comprises one of a fluorogenic molecule, molecular beacon, or another molecule that can be stimulated to emit photons that can be detected and quantified in a suitable detector.

41. (**Withdrawn**) A kit for detecting SARS coronavirus as claimed in Claim 38 wherein the detection molecule encodes any one of the DNA sequences of SEQ ID Nos. 21 to 25.